MODULEX-GRUPPEN
22.5.2024 18:36:27 CEST | Business Wire | Pressemeddelelse
Modulex Gruppen er glade for at kunne annoncere udnævnelsen af Mikkel Arreborg som Chief Finance og Operations Officer med base i koncernens hovedkvarter i Billund. Mikkel har en baggrund som CFO med en dokumenteret track record for strategisk finansielt lederskab og operationel ekspertise på tværs af forskellige brancher.
I løbet af sin tid som CFO hos Auto Solutions Group demonstrerede Mikkel enestående færdigheder i at styre finansielle operationer på tværs af et konglomerat af virksomheder. Hans ansvarsområder omfattede tilsyn med budgettering, finansiel rapportering og aktiv deltagelse i bestyrelsesmøder. Han stod især i spidsen for en omfattende omstrukturering af økonomiafdelingen og implementerede nye systemer og processer for at øge effektiviteten. Mikkel spillede en afgørende rolle i det succesfulde opkøb af Etac Bil i Norge, hvor han viste sin instrumentelle rolle i opkøb og integrationer.
"Det er mig en stor ære at blive en del af Modulex-teamet", siger Mikkel Arreborg. "Jeg er meget begejstret for at deltage i den spændende rejse, der ligger forude for koncernen, og den enestående mulighed for at lære af og bidrage til alle Modulex enheder på tværs af forskellige lande og kulturer."
Før han kom til Modulex Gruppen, havde Mikkel betydelige roller hos bl.a. PwC og BDO. Han har en kandidatgrad i revision og en diplomuddannelse i erhvervsøkonomi med speciale i regnskab og økonomistyring.
Ketil M. Staalesen, CEO i Modulex Gruppen, er begejstret for udnævnelsen af Mikkel og udtaler: "Jeg er virkelig begejstret for, at Mikkel har besluttet sig for at blive en del af vores team. Det er en meget vigtig rolle i fremtiden for den globale koncern, og det er en rolle, jeg arbejder meget tæt sammen med. Jeg var imponeret over Mikkels strategiske sans, hans umiddelbare observation af, hvordan han kunne gøre en forskel, og hans begejstring for at lære og lære alle forretningsenhederne at kende globalt."
Mikkel er en indflydelsesrig leder, der er forpligtet til at fremme et samarbejdsmiljø og bidrage til Modulex' formålsdrevne virksomhedskultur.
For mere information om Modulex, besøg vores hjemmeside https://modulex.com/ eller kontakt vores medierelationsteam på media@modulex.com
Om Modulex Gruppen:
Modulex blev grundlagt i 1963 af LEGO Koncernen og har siden 2009 været ejet af ledende partnere og eksterne investorer og er globalt førende inden for visuel kommunikation. Med rødder i dansk design excellence og et modulært skiltningskoncept har Modulex udviklet sin platform med design, wayfinding, skræddersyede løsninger og brandimplementeringer. I 2019 lancerede Modulex fabrikken i Billund, som er både ISO 9001 og 14001 certificeret, en bæredygtig produktlinje og blev tildelt Green Network-diplomet for 10. gang i træk. Den multinationale koncern har flere produktionsfaciliteter globalt. Koncernen er repræsenteret i over 300 byer i 45 lande.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240522566437/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
